Synairgen (LON:SNG) Stock Price Down 2.4% – Should You Sell?

Synairgen plc (LON:SNG)’s stock price fell 2.4% during mid-day trading on Tuesday . The stock traded as low as GBX 2.05 ($0.03) and last traded at GBX 2.19 ($0.03). 1,204,007 shares traded hands during trading, a decline of 10% from the average session volume of 1,343,892 shares. The stock had previously closed at GBX 2.25 ($0.03).

Synairgen Price Performance

The stock has a 50-day simple moving average of GBX 3.65 and a 200 day simple moving average of GBX 3.98. The stock has a market capitalization of £3.68 million, a P/E ratio of -60.93 and a beta of -2.23. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.35 and a current ratio of 6.77.

About Synairgen

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.

Synairgen is conducting a double blind, placebo-controlled clinical trial in COVID-19 patients (SG016).